



CIN NO.: L24230WB1982PLC034492

Date: 07th February, 2020

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Outcome of Board Meeting held on 07th February, 2020

This is to inform you that, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Director at its meeting was held at its Registered Office on Friday, 07th February, 2020 (**commenced at 11:30 A.M. and concluded at 12:40 P.M.**) have inter-alia considered, approved and adopted the following agenda:

1. Standalone Unaudited Financial Results of the Company for the 03rd quarter and nine months ended 31st December, 2019
2. Limited Review Report by the Statutory Auditors on Standalone Unaudited Financial Results for 03rd quarter ended 31st December, 2019
3. Appointment of M/s. Kumar Roybarman Prasanta and Associates (FRN: 330634E), Chartered Accountants, Kolkata as Internal Auditor of the Company for the Financial Year 2019-2020 pursuant to Section 138 of the Companies Act, 2013.
4. Appointment of M/s. Veenit Pal & Associates, Company Secretary, Mumbai as Secretarial Auditors of the Company for the Financial Year 2019-2020 pursuant to Section 204 to conduct Secretarial Audit of the Company.

This information is also available on Company's website: www.adinathbio.com and on the stock exchange website: www.cse-india.com.

The Company would be publishing Extract of Un-Audited Financial Result for the Quarter ended 31-12-2019, in accordance with Regulation 47(1) (b) of the Listing Regulation.


Request you to kindly take the above on record.

Thanking you,
Yours faithfully,

For Adinath Bio-Labs Limited

Kishan Singh
(Whole-Time Director)
(DIN: 07526266)


Encl.: As above.



Email: investors@adinathbio.com
Website: www.adinathbio.com

4, Netaji Subhas Road, 1st Floor, Kolkata – 700 001
Telephone: +91-33-22315718

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31st December, 2019							
PART I						(Amount in Rs.)	
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
1	Income from operations						
	(a) Net Sales / income from operations	-	-	-	-	-	-
	(b) Other Income	63,596	63,596	64,690	1,90,096	1,98,735	2,61,744
	Total income from operations (net)	63,596	63,596	64,690	1,90,096	1,98,735	2,61,744
2	Expenses						
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-	-
	(b) Employee benefits expense	1,36,409	1,14,783	69,528	3,93,425	2,03,004	3,14,643
	(c) Finance Cost	-	-	-	-	-	-
	(d) Depreciation and amortisation expense	13,394	13,394	25,269	40,182	77,788	1,02,996
	(e) Other expenses	79,015	1,17,801	81,814	4,57,884	27,93,008	51,98,137
	Total expenses	2,28,818	2,45,978	1,76,611	8,91,491	30,73,800	56,15,776
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(1,65,222)	(1,82,382)	(1,11,921)	(7,01,395)	(28,75,065)	(53,54,032)
4	Exceptional & Extraordinary Items	96,09,786	1,34,72,226	1,98,80,000	2,91,07,012	1,98,80,000	1,98,80,000
5	Profit / (Loss) before Tax (3+4)	(97,75,008)	(1,36,54,608)	(1,99,91,921)	(2,98,08,407)	(2,27,55,065)	(2,52,34,032)
6	Tax expense						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	(1,76,016)
	Earlier Years	-	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	-	(1,76,016)
7	Net Profit/(Loss) after tax(5+6)	(97,75,008)	(1,36,54,608)	(1,99,91,921)	(2,98,08,407)	(2,27,55,065)	(2,50,58,016)
8	Other Comprehensive Income / (Loss)	-	-	-	-	-	-
9	Total Comprehensive Income / (Loss) (7+ 8)	(97,75,008)	(1,36,54,608)	(1,99,91,921)	(2,98,08,407)	(2,27,55,065)	(2,50,58,016)
10	Paid-up equity share capital	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560	22,07,42,560
	(Face Value in Re.)	1	1	1	1	1	1
11	Earnings Per Share (not annualised except for year ended):						
	Basic & Diluted	(0.04)	(0.06)	(0.09)	(0.14)	(0.10)	(0.11)



CIN NO.: L24230WB1982PLC034492

Notes:

- 1 The above Unaudited Financial Results have been reviewed by the Audit committee and adopted by the Board of Directors at their meeting held on 07th February, 2020.
- 2 The results are based on the financial statements prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- 4 The amount of Rs. 96.10 lacs have been provided and charged to profit and loss account on account of doubtful receivables for quarter ended December 31, 2019.
- 5 The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter ended and nine months ended December 31, 2019 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and issued an unqualified report in this behalf.
- 6 Provisions for current year income tax and deferred tax will be made at the end of the year except for the earlier year which are accounted on the basis of assessment orders received by the company.
- 7 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

By order of the Board
For Adinath Bio-Labs Limited

Kishan Singh
Whole-Time Director
DIN No.:07526266

Date: 07th February, 2020

Place: Kolkata

Email: investors@adinathbio.com
Website: www.adinathbio.com

4, Netaji Subhas Road, 1st Floor, Kolkata – 700 001
Telephone: +91-33-22315718

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Adinath Bio-Labs Limited


We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the 03rd quarter and nine months ended on 31st December, 2019 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA & Co.
Chartered Accountants
FRN: 003822C


Kamal Piyush
Partner

UDIN: 20083399AAAAAB1999
Membership No.: 083399
Place: Kolkata
Date: 07/02/2020